Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry

Table 1 Baseline, diagnostic and medication characteristics of the two study groups: cases suffering from dementia with Lewy bodies versus Alzheimer’s disease patients

Characteristic	Dementia with Lewy bodies	Alzheimer’s disease	Pvalue
Characteristic	(n=634)	(n=9,161)	Pvalue
Gender			<0.001 ^a
Female	252 (39.7%)	5973 (65.2%)
Male	382 (60.3%)	3188 (34.8%)
Age (years)	76.5 (7.1)	77.6 (8.3)	<0.001 ^b
MMSE score	21.4 (5.0)	21.5 (5.0)	0.593^b
Body mass index (kg/m²)	24.4 (4.1)	24.3 (4.1)	0.565^b
Living place			<0.001 ^a
Own house	559 (88.2%)	8627 (94.4%)
Nursing home	75 (11.8%)	512 (5.6%)
Co-resident			<0.001 ^a
Yes	218 (36.0%)	3879 (44.0%)
No	387 (64.0%)	4938 (56.0%)
Medication (at the time of diagnosis)
Cholinesterase inhibitors	465 (73.6%)	6598 (72.7%)	0.272^a
NMDA antagonist	95 (15.0%)	895 (9.9%)	<0.001 ^a
Antidepressants	220 (34.8%)	2382 (26.3%)	<0.001 ^a
Antipsychotics	103 (16.3%)	447 (4.9%)	<0.001 ^a
Anxiolytics	84 (13.3%)	747 (8.2%)	<0.001 ^a
Hypnotics	106 (16.8%)	1292 (14.2%)	0.065^a
Cardiovascular drugs	365 (57.8%)	4825 (53.2%)	0.054^a
Total number of drugs	4.7 (3.0)	3.7 (2.9)	<0.001 ^b

Data presented as number (%) or mean (standard deviation). Statistically significant differences (P≤0.05) in bold. MMSE, Mini-Mental State Examination; NMDA, N-methyl d-aspartate. ^aPearson chi-square statistic. ^bIndependent-sample t test.

ISSN: 1758-9193